Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scottish MS study aims to predict disease course years in advance

NCT ID NCT06001138

Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 440 people with relapsing-remitting multiple sclerosis for 5 to 10 years after their diagnosis. Researchers will use brain scans, lab tests, and genetic information to find patterns that predict how the disease will progress. The goal is to help doctors and patients better understand what to expect and tailor treatments accordingly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors predict how multiple sclerosis will progress in each person, leading to more personalized treatment plans.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test any new therapy. Results may take years and might not apply to all MS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 440 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The overwhelming majority (98%) of FutureMS participants have given consent to be approached for future research. The study aims to retain 90% of the consented FutureMS cohort. The majority of participants that took part in FutureMS gave their consent to be contacted about future ethically approved research. These participants will be contact directly by a phone, email or post by the study team.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previous participants in FutureMS cohort * Capacity to provide informed consent Exclusion Criteria: * Not a participant of FutureMS inception cohort * Contraindication to MR brain imaging

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aberdeen Clinical Research Facility Royal Cornhill Hospital

    Aberdeen, AB25 2ZD, United Kingdom

  • Anne Rowling Regenerative Neurology Clinic

    Edinburgh, EH16 4SB, United Kingdom

  • Centre for Health Sciences Raigmore Hospital

    Inverness, IV2 3JH, United Kingdom

  • Dundee Clinical Research Centre Ninewells Hospital

    Dundee, DD1 9SY, United Kingdom

  • Glasgow Clinical Research Facility Queen Elizabeth University Hospital

    Glasgow, G51 4TF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.